Drug intelligence / Profile preview

anti-Eimeria tenella IgG2a

Development stage
Unknown
Lead developer
Pfizer
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intraperitoneal, Subcutaneous
01

Overview

anti-Eimeria tenella IgG2a is a monoclonal antibody of the IgG2a isotype specifically directed against antigens of *Eimeria tenella*, a protozoan parasite that causes coccidiosis in poultry. In the context of immunological research and preclinical drug development, this antibody is primarily utilized as an **isotype control**. Because its target is a non-mammalian pathogen, it does not bind to mouse or human proteins, making it an ideal negative control for evaluating the specific effects of other IgG2a-based therapeutic candidates (such as anti-IL25 antibodies). It allows researchers to account for non-specific binding or Fc-receptor-mediated biological activities in various experimental systems, including the Aldara-induced psoriasiform skin inflammation model and the IL25-mediated air pouch recruitment model.

Other names
anti-E. tenella isotype control antibodyanti-E. tenella IgG2aanti-Eimeria tenella monoclonal antibody

Beyond the preview

Go deeper on anti-Eimeria tenella IgG2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-Eimeria tenella IgG2a.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call